PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. The company operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. It offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. The company also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong’s name that provide Chinese medicine services and CCMG products. In addition, it engages in the plantation and trading of raw Chinese herbs; manufacture and sale of traditional Chinese medicine decoction pieces; provision of modernized Chinese medicine services, Chinese medical diagnostic services; and research and development of bio-based polymeric materials. The company sells its products to hospitals, healthcare institutions, mobile clinics, and medicine practitioners, as well as operates an online platform. The company was incorporated in 1998 and is headquartered in Tai Po, Hong Kong.
Metrics to compare | 1498 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1498PeersSector | |
---|---|---|---|---|
P/E Ratio | −5.1x | 8.6x | −0.5x | |
PEG Ratio | −0.08 | 0.02 | 0.00 | |
Price/Book | 1.6x | 0.8x | 2.6x | |
Price / LTM Sales | 0.5x | 2.1x | 3.2x | |
Upside (Analyst Target) | - | 28.6% | 41.9% | |
Fair Value Upside | Unlock | 13.7% | 4.3% | Unlock |